Developer docs
API playgroundTry for free, no card

Search company profiles

Mauna Kea Technologies

Full company profile

uuid00036tc

Namestring
Mauna Kea Technologies
Legal namestring
Mauna Kea Technologies
Company typeenum
Public
Founded yearint
2000
Descriptiontext

Mauna Kea Technologies is a Paris-based, publicly listed (Euronext Growth Paris: ALMKT) medical device company founded in 2000 by astrophysicist Sacha Loiseau, commercializing the Cellvizio platform — the first commercial real-time, in vivo cellular imaging system based on probe- and needle-based Confocal Laser Endomicroscopy (CLE). The platform works through confocal miniprobes (CholangioFlex, ColoFlex UHD, GastroFlex UHD, AQ-Flex 19) inserted into the working channel of standard endoscopes to deliver cellular-level visualization during procedures in gastroenterology, pulmonology, and urology. The technology originated from research at NASA's Jet Propulsion Laboratory and is supported by 1,300+ clinical papers and 20 FDA clearances.

The company operates a hybrid razor-and-blade business model combining capital equipment sales (Cellvizio systems, including the next-generation Gen 3) with recurring consumable revenue from disposable miniprobes, supplemented by tailored multi-year service contracts. Go-to-market is direct enterprise sales in the US (Allston, MA office) and France, with a worldwide distributor network covering 17+ countries across EMEA, APAC, and select LATAM markets. Customer base consists primarily of academic medical centers and hospital systems (e.g., Mayo Clinic, University Hospital Basel, Bern University Hospital, Amsterdam UMC). Beyond the core platform, Mauna Kea has built the CellTolerance consumer-pay diagnostic program for IBS/food intolerance (€1M sales in 2025) and pursues strategic co-development partnerships with Johnson & Johnson, Telix Pharmaceuticals (19.33% shareholder), and TaeWoong Medical to extend the technology into urologic oncology, AI-assisted imaging, and pancreatic cyst management.

In 2024, total sales were €7.6 million; the company completed a financial restructuring in November 2025 that reduced debt from €40M to €12M and extended cash runway to H2 2027. Q1 2026 core sales grew +68% at constant exchange rates, and the first half of 2026 added regulatory approvals in the UAE, Turkey, Switzerland, and the UK, plus CE MDR certification for Cellvizio, supporting an accelerating growth trajectory.

Short descriptiontext

Mauna Kea Technologies (Paris, Euronext Growth Paris: ALMKT) designs and commercializes the Cellvizio platform, a probe-based confocal laser endomicroscopy system providing real-time in vivo cellular imaging for gastroenterology, pulmonology, and urology, selling systems and consumables to hospitals and academic medical centers worldwide.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersAllston, United States
HQ citystring
Allston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
optical biopsy devices, confocal laser endomicroscopy, in vivo cellular imaging, medical endoscopy equipment, diagnostic imaging platform
Industry3 codes
PRIMARYHLAHADAB
Endoscopy Systems & Accessories (Scopes, Cameras, Light Sources, Insufflation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHLAHADAN
Endoscopic Therapeutic & Access Devices (Trocars, dilators, biopsy/ablation tools)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHLAGAIAE
Microscopy, Imaging & Flow Cytometry Instruments
NAICS code2 codes
  • Surgical and Medical Instrument Manufacturing339112
  • Medical Equipment and Supplies Manufacturing3391
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Medical Imaging Devices
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Cellvizio System Sales
TypeHardware Sales
Description

Sale of Cellvizio imaging systems to healthcare institutions and hospitals

maunakeatech.com
2Confocal Miniprobes (Consumables)
TypeHardware Sales
Description

Sale of disposable confocal miniprobes used during procedures - represents recurring revenue stream from consumables

maunakeatech.com
3Service Contracts
TypeSubscription Recurring
Description

Tailored service contracts including preventative maintenance, software upgrades, on-site maintenance, loaner service, and predictive maintenance

maunakeatech.com
4CellTolerance Program
TypeSubscription Recurring
Description

Food intolerance diagnostic program using Cellvizio reached €1 million in sales in 2025, representing new revenue stream

morningstar.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations, Others
Pricing details1 tier
1Cellvizio Service Contract - customized maintenance and support packages
ModelOtherBilling cadenceMulti-year contract
Notes

Service contracts include preventative maintenance, regular software upgrades, on-site maintenance, loaner service, log files-based predictive maintenance, and on-demand support. Tailored to customer needs.

maunakeatech.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1Cellvizio
Description

The real-time in vivo cellular imaging platform using Confocal Laser Endomicroscopy (CLE) technology for cellular visualization across multiple medical specialties.

maunakeatech.com
+2 more records
Core offering1 text field

Mauna Kea Technologies designs, develops, manufactures, and sells the Cellvizio platform, a real-time in vivo cellular imaging system based on Confocal Laser Endomicroscopy (CLE) technology. The platform uses disposable Confocal Miniprobes inserted through standard endoscopes or biopsy needles to deliver cellular-level visualization during gastroenterology, pulmonology, and urology procedures, sold to hospitals, academic medical centers, and specialty clinics as a system-plus-consumables model with associated service contracts.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • 100% relapse-free rate over 24 months for UC patients achieving triple healing (0 of 29), vs ~33% relapse rate in non-achievers
+6 more records
Product overview1 text field

Mauna Kea Technologies offers the Cellvizio® platform, a real-time in vivo cellular imaging system based on Confocal Laser Endomicroscopy technology. The platform serves multiple medical specialties (gastroenterology, pulmonology, urology) through a modular approach: the core Cellvizio® system works with specialized Confocal Miniprobes™ (CholangioFlex™, ColoFlex™ UHD, GastroFlex™ UHD, AQ-Flex™ 19) designed for different anatomical regions and procedures. The company has developed CellTolerance®, a diagnostic application powered by Cellvizio for food intolerance testing in IBS patients. The portfolio includes the latest Cellvizio Gen 3 system and spans clinical indications such as pancreatic cysts, Barrett's esophagus, colorectal lesions, inflammatory bowel disease, lung nodules, and urologic applications.

Product and service8 records
1Cellvizio
CategoryMedical imaging system
Description

Real-time in vivo cellular imaging platform using probe-based and needle-based Confocal Laser Endomicroscopy (pCLE/nCLE) that delivers cellular visualization virtually anywhere in the human body through Confocal Miniprobes inserted into standard endoscopes. Sold to hospitals, gastroenterologists, pulmonologists, and urologists.

2Cellvizio Gen 3 System
CategoryMedical imaging system
Description

Next-generation version of the Cellvizio platform with enhanced imaging capabilities for real-time in vivo cellular visualization. Received CE MDR certification and regulatory approvals across multiple jurisdictions including UAE, Turkey, Switzerland, and the UK.

3CholangioFlex Miniprobe
CategoryImaging consumable probe
Description

Disposable confocal miniprobe for real-time imaging of biliary and pancreatic ducts during ERCP procedures, enabling in vivo characterization of bilio-pancreatic strictures. Sold as a consumable to gastroenterology departments.

4ColoFlex UHD Miniprobe
CategoryImaging consumable probe
Description

Ultra-high definition disposable confocal miniprobe for assessment of colorectal lesions during colonoscopy, enabling differentiation between neoplastic and non-neoplastic tissue. Sold as a consumable to gastroenterology departments.

5GastroFlex UHD Miniprobe
CategoryImaging consumable probe
Description

Ultra-high definition disposable confocal miniprobe for gastrointestinal tract imaging, used in procedures for gastric disease, Barrett's esophagus, and inflammatory bowel disease assessment. Sold as a consumable to gastroenterology departments.

6AQ-Flex 19 Miniprobe
CategoryImaging consumable probe
Description

Needle-based disposable confocal miniprobe for lung lesion characterization, deployed through biopsy needles during EBUS-TBNA, EUS-FNA, and TBNA procedures for real-time diagnosis of peripheral lung nodules. Sold as a consumable to pulmonology departments.

7CellTolerance Program
CategoryDiagnostic program
Description

Multidisciplinary diagnostic program powered by Cellvizio for identifying food intolerances associated with Irritable Bowel Syndrome through real-time visualization of live cell response during endoscopy procedures (C-FIT test). Reached €1 million in sales in 2025 and is targeted at GI clinics serving IBS patients.

8Cellvizio Service Contracts
CategoryService and support
Description

Tailored multi-year service contracts for Cellvizio systems including preventative maintenance, regular software upgrades, on-site maintenance, loaner service, log files-based predictive maintenance, and on-demand technical support. Sold to existing Cellvizio system customers.

Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-12-03
Description

Exclusive partnership to integrate Cellvizio with TaeWoong's EUS-guided therapeutic devices in the US. Creates comprehensive pancreatic cyst management solution combining imaging with therapy. Aims to streamline workflow, improve diagnostic accuracy, and enhance patient care for pancreatic conditions.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Strategic collaboration with Johnson & Johnson expanding reach of Cellvizio technology in gastroenterology and other therapeutic areas including robotics surgery and AI-assisted imaging.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership to create first U.S. Center of Excellence for the use of Cellvizio to identify and treat food intolerance in adults.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global leader in endoscopy systems and accessories across GI, pulmonology, and urology. Competes with Cellvizio as the dominant platform on which miniprobes are inserted, and could integrate comparable cellular imaging into its ecosystem.

TypeBroad incumbent
Description

Major medtech player with significant endoscopy, pulmonology, and urology franchises. Overlaps with Cellvizio in interventional pulmonology and urology, and has scale advantages in procedure-enabling devices.

TypeBroad incumbent
Description

Endoscopy systems and accessories manufacturer. Directly comparable as the supplier of endoscopes through which Cellvizio miniprobes operate, and a potential integrator of cellular imaging.

TypeBroad incumbent
Description

Endoscopy systems provider with growing presence in GI imaging and AI-assisted endoscopy. Competes broadly with Cellvizio in gastroenterology procedure suites.

TypeDirect peer
Description

Probe-based optical coherence tomography imaging during endoscopy, the closest direct competitor to Cellvizio's in vivo probe-based cellular imaging approach in GI.

TypeBroad incumbent
Description

Endoscopy manufacturer serving pulmonology, urology, and GI. Comparable as an endoscopy systems provider that competes for hospital capital budgets and could integrate probe-based imaging.

TypeBroad incumbent
Description

Diversified medtech incumbent with GI, pulmonology, and urology franchises. Overlaps with Cellvizio across multiple procedure types and at large hospital IDNs.

TypeBroad incumbent
Description

Medical device major with endoscopy and surgical visualization offerings. Competes for hospital capital across the same procedure suites where Cellvizio is deployed.

TypeBroad incumbent
Description

Surgical robotics and visualization leader. Strategic overlap with Cellvizio's stated expansion into robotics surgery and AI-assisted imaging through its Johnson & Johnson partnership.

TypeOthers
Description

Strategic partner (JJDC investor and Cellvizio collaboration partner) with overlapping GI and surgical visualization interests. Relevant as both partner and potential acquirer/competitor.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Mauna Kea Technologies

Medical Imaging Devicesmaunakeatech.com

Mauna Kea Technologies (Paris, Euronext Growth Paris: ALMKT) designs and commercializes the Cellvizio platform, a probe-based confocal laser endomicroscopy system providing real-time in vivo cellular imaging for gastroenterology, pulmonology, and urology, selling systems and consumables to hospitals and academic medical centers worldwide.

What Mauna Kea Technologies does

Mauna Kea Technologies is a Paris-based, publicly listed (Euronext Growth Paris: ALMKT) medical device company founded in 2000 by astrophysicist Sacha Loiseau, commercializing the Cellvizio platform — the first commercial real-time, in vivo cellular imaging system based on probe- and needle-based Confocal Laser Endomicroscopy (CLE). The platform works through confocal miniprobes (CholangioFlex, ColoFlex UHD, GastroFlex UHD, AQ-Flex 19) inserted into the working channel of standard endoscopes to deliver cellular-level visualization during procedures in gastroenterology, pulmonology, and urology. The technology originated from research at NASA's Jet Propulsion Laboratory and is supported by 1,300+ clinical papers and 20 FDA clearances.

The company operates a hybrid razor-and-blade business model combining capital equipment sales (Cellvizio systems, including the next-generation Gen 3) with recurring consumable revenue from disposable miniprobes, supplemented by tailored multi-year service contracts. Go-to-market is direct enterprise sales in the US (Allston, MA office) and France, with a worldwide distributor network covering 17+ countries across EMEA, APAC, and select LATAM markets. Customer base consists primarily of academic medical centers and hospital systems (e.g., Mayo Clinic, University Hospital Basel, Bern University Hospital, Amsterdam UMC). Beyond the core platform, Mauna Kea has built the CellTolerance consumer-pay diagnostic program for IBS/food intolerance (€1M sales in 2025) and pursues strategic co-development partnerships with Johnson & Johnson, Telix Pharmaceuticals (19.33% shareholder), and TaeWoong Medical to extend the technology into urologic oncology, AI-assisted imaging, and pancreatic cyst management.

In 2024, total sales were €7.6 million; the company completed a financial restructuring in November 2025 that reduced debt from €40M to €12M and extended cash runway to H2 2027. Q1 2026 core sales grew +68% at constant exchange rates, and the first half of 2026 added regulatory approvals in the UAE, Turkey, Switzerland, and the UK, plus CE MDR certification for Cellvizio, supporting an accelerating growth trajectory.

Mauna Kea Technologies firmographics

Firmographics
Name
Mauna Kea Technologies
Legal name
Mauna Kea Technologies
Website
https://maunakeatech.com
Company type
Public
Founded year
2000
Operating status
Operating
Headcount range
101–250 employees
Short description
Mauna Kea Technologies (Paris, Euronext Growth Paris: ALMKT) designs and commercializes the Cellvizio platform, a probe-based confocal laser endomicroscopy system providing real-time in vivo cellular imaging for gastroenterology, pulmonology, and urology, selling systems and consumables to hospitals and academic medical centers worldwide.
Ownership category
akta.pro rank

Mauna Kea Technologies industry classification

Industry
Product category
Medical Imaging Devices
NAICS
Surgical and Medical Instrument Manufacturing (339112), Medical Equipment and Supplies Manufacturing (3391)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHADAB
Endoscopy Systems & Accessories (Scopes, Cameras, Light Sources, Insufflation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHLAHADAN
Endoscopic Therapeutic & Access Devices (Trocars, dilators, biopsy/ablation tools)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHLAGAIAE
Microscopy, Imaging & Flow Cytometry Instruments

Keywords

  • Optical biopsy devices
  • Confocal laser endomicroscopy
  • In vivo cellular imaging
  • Medical endoscopy equipment
  • Diagnostic imaging platform

Where Mauna Kea Technologies is headquartered

Location

Headquarters

HQ city
Allston
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Mauna Kea Technologies business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations, Others

Revenue model

  1. Cellvizio System Sales: Sale of Cellvizio imaging systems to healthcare institutions and hospitals
  2. Confocal Miniprobes (Consumables): Sale of disposable confocal miniprobes used during procedures - represents recurring revenue stream from consumables
  3. Service Contracts: Tailored service contracts including preventative maintenance, software upgrades, on-site maintenance, loaner service, and predictive maintenance
  4. CellTolerance Program: Food intolerance diagnostic program using Cellvizio reached €1 million in sales in 2025, representing new revenue stream

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCellvizio Service Contract - customized maintenance and support packages

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Mauna Kea Technologies product offering

Product offering

Core offering

Mauna Kea Technologies designs, develops, manufactures, and sells the Cellvizio platform, a real-time in vivo cellular imaging system based on Confocal Laser Endomicroscopy (CLE) technology. The platform uses disposable Confocal Miniprobes inserted through standard endoscopes or biopsy needles to deliver cellular-level visualization during gastroenterology, pulmonology, and urology procedures, sold to hospitals, academic medical centers, and specialty clinics as a system-plus-consumables model with associated service contracts.

Product overview

Mauna Kea Technologies offers the Cellvizio® platform, a real-time in vivo cellular imaging system based on Confocal Laser Endomicroscopy technology. The platform serves multiple medical specialties (gastroenterology, pulmonology, urology) through a modular approach: the core Cellvizio® system works with specialized Confocal Miniprobes™ (CholangioFlex™, ColoFlex™ UHD, GastroFlex™ UHD, AQ-Flex™ 19) designed for different anatomical regions and procedures. The company has developed CellTolerance®, a diagnostic application powered by Cellvizio for food intolerance testing in IBS patients. The portfolio includes the latest Cellvizio Gen 3 system and spans clinical indications such as pancreatic cysts, Barrett's esophagus, colorectal lesions, inflammatory bowel disease, lung nodules, and urologic applications.

Differentiator

Problem solved

Functional benefit

Brands

  • Cellvizio: The real-time in vivo cellular imaging platform using Confocal Laser Endomicroscopy (CLE) technology for cellular visualization across multiple medical specialties.
  • CellTolerance
  • C-FIT

Products and services

  • Cellvizio Real-time in vivo cellular imaging platform using probe-based and needle-based Confocal Laser Endomicroscopy (pCLE/nCLE) that delivers cellular visualization virtually anywhere in the human body through Confocal Miniprobes inserted into standard endoscopes. Sold to hospitals, gastroenterologists, pulmonologists, and urologists.
  • Cellvizio Gen 3 System Next-generation version of the Cellvizio platform with enhanced imaging capabilities for real-time in vivo cellular visualization. Received CE MDR certification and regulatory approvals across multiple jurisdictions including UAE, Turkey, Switzerland, and the UK.
  • CholangioFlex Miniprobe Disposable confocal miniprobe for real-time imaging of biliary and pancreatic ducts during ERCP procedures, enabling in vivo characterization of bilio-pancreatic strictures. Sold as a consumable to gastroenterology departments.
  • ColoFlex UHD Miniprobe Ultra-high definition disposable confocal miniprobe for assessment of colorectal lesions during colonoscopy, enabling differentiation between neoplastic and non-neoplastic tissue. Sold as a consumable to gastroenterology departments.
  • GastroFlex UHD Miniprobe Ultra-high definition disposable confocal miniprobe for gastrointestinal tract imaging, used in procedures for gastric disease, Barrett's esophagus, and inflammatory bowel disease assessment. Sold as a consumable to gastroenterology departments.
  • AQ-Flex 19 Miniprobe Needle-based disposable confocal miniprobe for lung lesion characterization, deployed through biopsy needles during EBUS-TBNA, EUS-FNA, and TBNA procedures for real-time diagnosis of peripheral lung nodules. Sold as a consumable to pulmonology departments.
  • CellTolerance Program Multidisciplinary diagnostic program powered by Cellvizio for identifying food intolerances associated with Irritable Bowel Syndrome through real-time visualization of live cell response during endoscopy procedures (C-FIT test). Reached €1 million in sales in 2025 and is targeted at GI clinics serving IBS patients.
  • Cellvizio Service Contracts Tailored multi-year service contracts for Cellvizio systems including preventative maintenance, regular software upgrades, on-site maintenance, loaner service, log files-based predictive maintenance, and on-demand technical support. Sold to existing Cellvizio system customers.

Quantifiable outcome

  • 100% relapse-free rate over 24 months for UC patients achieving triple healing (0 of 29), vs ~33% relapse rate in non-achievers
  • +6 more outcomes

Companies that use Mauna Kea Technologies

Customer profile

Named customers6 records

Segments5 records

Ideal customer profiles2 records

Mauna Kea Technologies technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Mauna Kea Technologies partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered major and core.

  • TaeWoong Medical USAmajorStrategic or Co-development Partner · 3 December 2025Exclusive partnership to integrate Cellvizio with TaeWoong's EUS-guided therapeutic devices in the US. Creates comprehensive pancreatic cyst management solution combining imaging with therapy. Aims to streamline workflow, improve diagnostic accuracy, and enhance patient care for pancreatic conditions.
  • Johnson & JohnsoncoreStrategic or Co-development PartnerStrategic collaboration with Johnson & Johnson expanding reach of Cellvizio technology in gastroenterology and other therapeutic areas including robotics surgery and AI-assisted imaging.
  • MetrodoracoreStrategic or Co-development PartnerPartnership to create first U.S. Center of Excellence for the use of Cellvizio to identify and treat food intolerance in adults.

Scale indicators12 records

Recent moves8 records

Expansion highlights6 records

Mauna Kea Technologies competitors and assessment

Company assessment

Broad incumbents

  • Olympus Corporation: Global leader in endoscopy systems and accessories across GI, pulmonology, and urology. Competes with Cellvizio as the dominant platform on which miniprobes are inserted, and could integrate comparable cellular imaging into its ecosystem.
  • Boston Scientific: Major medtech player with significant endoscopy, pulmonology, and urology franchises. Overlaps with Cellvizio in interventional pulmonology and urology, and has scale advantages in procedure-enabling devices.
  • HOYA Corporation (Pentax Medical): Endoscopy systems and accessories manufacturer. Directly comparable as the supplier of endoscopes through which Cellvizio miniprobes operate, and a potential integrator of cellular imaging.
  • Fujifilm Healthcare: Endoscopy systems provider with growing presence in GI imaging and AI-assisted endoscopy. Competes broadly with Cellvizio in gastroenterology procedure suites.
  • KARL STORZ SE & Co. KG: Endoscopy manufacturer serving pulmonology, urology, and GI. Comparable as an endoscopy systems provider that competes for hospital capital budgets and could integrate probe-based imaging.
  • Medtronic: Diversified medtech incumbent with GI, pulmonology, and urology franchises. Overlaps with Cellvizio across multiple procedure types and at large hospital IDNs.
  • Stryker Corporation: Medical device major with endoscopy and surgical visualization offerings. Competes for hospital capital across the same procedure suites where Cellvizio is deployed.
  • Intuitive Surgical: Surgical robotics and visualization leader. Strategic overlap with Cellvizio's stated expansion into robotics surgery and AI-assisted imaging through its Johnson & Johnson partnership.

Direct peers

  • NinePoint Medical (NvisionVLE Imaging): Probe-based optical coherence tomography imaging during endoscopy, the closest direct competitor to Cellvizio's in vivo probe-based cellular imaging approach in GI.

Others

  • Johnson & Johnson (MedTech): Strategic partner (JJDC investor and Cellvizio collaboration partner) with overlapping GI and surgical visualization interests. Relevant as both partner and potential acquirer/competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Mauna Kea Technologies social profiles

Digital presence

Mauna Kea Technologies compliance and trust

Trust signal

Compliance3 records

Mauna Kea Technologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Mauna Kea Technologies leadership team

Management profile

Number of profiles

Profiles12 records

Mauna Kea Technologies funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Mauna Kea Technologies M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mauna Kea Technologies

What does Mauna Kea Technologies do?

Mauna Kea Technologies designs, develops, manufactures, and sells the Cellvizio platform, a real-time in vivo cellular imaging system based on Confocal Laser Endomicroscopy (CLE) technology. The platform uses disposable Confocal Miniprobes inserted through standard endoscopes or biopsy needles to deliver cellular-level visualization during gastroenterology, pulmonology, and urology procedures, sold to hospitals, academic medical centers, and specialty clinics as a system-plus-consumables model with associated service contracts.

Is Mauna Kea Technologies a public or private company?

Mauna Kea Technologies is a public company. It is classified as public and is currently operating.

When was Mauna Kea Technologies founded?

Mauna Kea Technologies was founded in 2000. It employs 101 to 250 people.

Where is Mauna Kea Technologies based?

Mauna Kea Technologies is headquartered in Allston, United States, in the North America region.

How does Mauna Kea Technologies make money?

Four revenue lines are on record. Cellvizio System Sales are the primary driver. The others are confocal Miniprobes (Consumables), service Contracts and cellTolerance Program.

Who are Mauna Kea Technologies's main competitors?

Broad incumbents on record are Olympus Corporation, Boston Scientific, HOYA Corporation (Pentax Medical), Fujifilm Healthcare, KARL STORZ SE & Co. KG, Medtronic, Stryker Corporation and Intuitive Surgical. NinePoint Medical (NvisionVLE Imaging) is listed as a direct peer. Johnson & Johnson (MedTech) is listed as an others.

Does Mauna Kea Technologies have an API?

No public API is recorded for Mauna Kea Technologies.

What industry is Mauna Kea Technologies in?

Mauna Kea Technologies's product category is Medical Imaging Devices. Its primary akta.pro industry code is HLAHADAB, Endoscopy Systems & Accessories (Scopes, Cameras, Light Sources, Insufflation), with a secondary code of HLAHADAN, Endoscopic Therapeutic & Access Devices (Trocars, dilators, biopsy/ablation tools). Its NAICS code is 339112 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewMauna Kea Technologies Q3 2026 Earnings Call Is LiveMauna Kea Technologies' Q3 2026 earnings call is live, with executives set to discuss financial results and answer analyst questions. The call may include surprise news, and management commentary on demand, margins, or capital spending could move markets.TradingViewALMKT: 9M sales rebounded, while a U.S. staffing reset and system pipeline set up the Q4 pushMauna Kea Technologies reported 9M product sales up 24% to €4,409K, driven by 128% growth in EMEA and Rest of World. Q3 fell 11% due to U.S. staffing gaps and system timing, but a completed U.S. team and international pipeline support the Q4 push.Business Wire BlogMauna Kea Technologies Reports Nine-Month 2026 Sales of €4.4 Million, Up 24% at Constant Exchange RatesMauna Kea Technologies reported nine-month 2026 sales of €4.4 million, up 24% at constant exchange rates, with recurring revenue up 17%. Third-quarter sales fell 11% at CER to €1.2 million, but the company expects a historically strong fourth quarter. It also announced a fully staffed U.S. sales team and an operational partnership with TaeWoong.TradingViewALMKT: 9M sales rose 24% CER, led by international growth and CellToleranceMauna Kea Technologies reported nine-month sales up 24% to €4.4m, with Europe and Rest of World up 128% and CellTolerance up 47%. Q3 sales fell 11% due to U.S. staffing gaps, but all territories are now staffed with funding runway to end-2027.TradingViewALMKT: 9M revenue grew 24% CER, while U.S. sales coverage and funding runway strengthenedMauna Kea Technologies reported Q3 revenue of €4.4M, up 24% CER, driven by international and recurring growth. U.S. sales vacancies were filled, and funding is expected to extend through end-2027.Business Wire BlogMauna Kea Technologies Announces 2026 Half-Year ResultsMauna Kea Technologies reported H1 2026 product and service revenue of €3.2 million, up 37% year-over-year, with gross margin at 65%. Operating loss was €4.2 million, and net loss was €4.8 million. The company extended financial visibility to end of 2027 with renewed support from Vester Finance.YahooMauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share CapitalMauna Kea Technologies reported its share capital as of August 31, 2026, with 198,626,997 shares in circulation and 199,714,048 total voting rights. The company, a medical device firm, manufactures Cellvizio, a real-time in vivo cellular imaging platform.Business Wire BlogMauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share CapitalMauna Kea Technologies reported its share capital for August 31, 2026, with 198,626,997 shares in circulation and 199,714,048 voting rights. The company, a medical device maker, also disclosed that 3,100,000 new shares were issued during the month.Business Wire BlogMauna Kea Technologies Announces Publication of a Landmark Systematic Review and Meta-Analysis Reinforcing the Diagnostic Accuracy and Clinical Impact of Cellvizio in Upper Gastrointestinal CancerMauna Kea Technologies announced the publication of an independent systematic review and meta-analysis of probe-based confocal laser endomicroscopy in upper gastrointestinal cancer, conducted and funded by Korea's National Evidence-Based Healthcare Collaborating Agency. The study pooled 33 studies and 2,350 patients, finding pCLE-guided biopsies cut the mean number of biopsies per patient by 48.5%, from 6.8 to 3.5. The company said the evidence may help broaden reimbursement coverage in the United States.Business Wire BlogMauna Kea Technologies: Monthly information regarding the total number of voting rights and shares comprising the share capitalMauna Kea Technologies filed its monthly regulatory disclosure on August 7, 2026, reporting share capital and voting rights as of July 31, 2026, with 195,296,487 shares in circulation and 196,383,354 total voting rights. The filing, required under Article L233-8-II of the French Commercial Code and Article 223-16 of AMF General Regulations, was made to Euronext Growth Paris (ISIN: FR0010609263, Ticker: ALMKT).